242 related articles for article (PubMed ID: 28237828)
21. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
22. The impact of anti-HBV treatment on the occurrence and recurrence of hepatocellular carcinoma: focus on Asian studies.
Yang X; Gao JY; Wang J; Cheng J
Discov Med; 2015 Feb; 19(103):89-99. PubMed ID: 25725223
[TBL] [Abstract][Full Text] [Related]
23. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
[TBL] [Abstract][Full Text] [Related]
24. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
Hu HH; Liu J; Lin YL; Luo WS; Chu YJ; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; You SL; Yang HI; Chen CJ;
Gut; 2016 Sep; 65(9):1514-21. PubMed ID: 26642861
[TBL] [Abstract][Full Text] [Related]
25. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
26. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
Liu S; Deng R; Zhou B; Liang X; Liu Z; Peng J; Chen J; Zhou Y; Guo Y; Chen Y; Li W; Shen S; Lu X; Zhao S; Liao X; Liang H; Lan Y; Hou J; Fan R; Sun J
J Infect Dis; 2022 Sep; 226(5):881-890. PubMed ID: 34931674
[TBL] [Abstract][Full Text] [Related]
27. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.
Arends P; Sonneveld MJ; Zoutendijk R; Carey I; Brown A; Fasano M; Mutimer D; Deterding K; Reijnders JG; Oo Y; Petersen J; van Bömmel F; de Knegt RJ; Santantonio T; Berg T; Welzel TM; Wedemeyer H; Buti M; Pradat P; Zoulim F; Hansen B; Janssen HL;
Gut; 2015 Aug; 64(8):1289-95. PubMed ID: 25011935
[TBL] [Abstract][Full Text] [Related]
28. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
Wong YJ; Nguyen VH; Yang HI; Li J; Le MH; Wu WJ; Han NX; Fong KY; Chen E; Wong C; Rui F; Xu X; Xue Q; Hu XY; Leow WQ; Goh GB; Cheung R; Wong G; Wong VW; Yu MW; Nguyen MH
Clin Mol Hepatol; 2023 Jul; 29(3):705-720. PubMed ID: 37157776
[TBL] [Abstract][Full Text] [Related]
29. [Effect of interferon or nucleos(t)ide analogs on hepatitis B-related hepatocellular carcinoma].
Liu ZH; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):842-845. PubMed ID: 31941239
[TBL] [Abstract][Full Text] [Related]
30. Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues.
Tawada A; Chiba T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Arai M; Kanda T; Shinozaki M; Goto N; Nagashima K; Yokosuka O
Oncology; 2016; 90(4):199-208. PubMed ID: 26934505
[TBL] [Abstract][Full Text] [Related]
31. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
Han C; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
[TBL] [Abstract][Full Text] [Related]
32. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
33. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
34. [Liver histological status and clinic outcome in HBeAg-negative chronic hepatitis B with low viral load].
Deng DL; Jiang JN; Su MH; Wang RM; Zang WW; Ling XZ; Wei HL; Liang XS; Zhou HK; He WM; Guo RS
Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1013-1017. PubMed ID: 34865348
[No Abstract] [Full Text] [Related]
35. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
Su MH; Lu AL; Li SH; Zhong SH; Wang BJ; Wu XL; Mo YY; Liang P; Liu ZH; Xie R; He LX; Fu WD; Jiang JN
World J Gastroenterol; 2015 Dec; 21(46):13087-94. PubMed ID: 26673249
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature.
Afifi AM; Elgenidy A; Hashim M; Awad AK; Jalal PK
Rev Med Virol; 2022 Nov; 32(6):e2353. PubMed ID: 35441759
[TBL] [Abstract][Full Text] [Related]
37. High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Lin CC; Bair MJ; Liu CY; Lin ZY; Chen CJ; Chen MJ; Chu CH; Wang HY; Shih SC; Wang TE
Medicine (Baltimore); 2019 Jan; 98(1):e13818. PubMed ID: 30608393
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States.
Wan DW; Tzimas D; Smith JA; Kim S; Araujo J; David R; Lobach I; Sarpel U
Am J Gastroenterol; 2011 Nov; 106(11):1994-2000. PubMed ID: 21912436
[TBL] [Abstract][Full Text] [Related]
39. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
[TBL] [Abstract][Full Text] [Related]
40. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]